Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Dec 2018
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Mesothelioma
- Focus Proof of concept; Therapeutic Use
- 17 Dec 2018 According to a PharmaMar media release, results from this trial are expected in early 2019.
- 25 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Sep 2017 Status changed from not yet recruiting to recruiting.